Research In Motion Ltd (BBRY) & Other Upgrades You Should Consider

So, why are these analysts so excited about ISIS-APOCIIIRx? The answer lies in the targeted patient population, those with high triglycerides and type 2 diabetes. This is a drug that produced an 88% reduction in Apoc-III (diabetes related) and a 72% reduction in triglycerides, which proves the drug is potent and that the company’s platform is working well on two hard-to-treat areas.

Truthfully, there was a belief that this particular product would not perform well in Phase trials. Thus, the unexpected surprise has produced large gains. As a highly diversified company, and with a market cap of $3 billion, I tend to like this company. Moreover, I believe that this data will lead ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) to capture a market – those at high risk of cardiovascular disease development and pancreatitis – and it is estimated to produce sales of $500 million; that’s just with this one drug!

Final Thoughts

I like the calls from each of these bullish yet very different upgrades. Since ISIS-APOCIIIRx is not expected to generate sales in the near future, and Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA)’s new leadership is still unproven, I tend to like BlackBerry the best.

The research from the noted Research In Motion Ltd (NASDAQ:BBRY) analysts is all due to channel checks, and with the stock trading at just 0.64 times sales I think the market is discounting BB10’s global success. Sure, 3.5 million units might be disappointing to some, but this company has come a long way over the last year and I think it deserves your due diligence.

Brian Nichols has no position in any stocks mentioned. The Motley Fool recommends Ulta Salon, Cosmetics & Fragrance. The Motley Fool owns shares of Ulta Salon, Cosmetics & Fragrance. Brian is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article 3 Upgrades You Should Consider originally appeared on Fool.com and is written by Brian Nichols.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.